CTSC and bronchiectasis: As cathepsin C (CatC; also known as dipeptidyl peptidase 1) activates NSPs in the bone marrow during myelopoiesis [4], CatC inhibition is expected to reduce NSP activity in the lungs of patients with bronchiectasis, thereby restoring the protease/antiprotease balance.